Komori
ReproCELL (4978) · PolicyRestated

Ensuring Clinical Laboratory Test Accuracy and Quality Control Activities

First written in FY2017. 5 of 7 entries say "Restated". Latest entry: FY2021.

7entries
5years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2017RestatedFY2020 – FY20212017: 120172018: 020182019: 020192020: 420202021: 22021
Same theme, other companies
Clinical Laboratory Testing Quality Control and Quality Assurance FrameworkA theme 2 companies write about · 0 as a headwind · 2 as a tailwind

1 other company's latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2021RestatedAnnual report

    「The Company’s registered laboratory has been accredited by the Japanese Society for Histocompatibility and Immunogenetics as an “Accredited Histocompatibility Testing Registered Facility.”」

    The Company reiterated its accreditation relating to the quality and contract testing structure for clinical testing.
  2. FY2021-Q3RestatedAnnual report

    「The Company’s registered laboratory has been accredited by the Japanese Society for Histocompatibility and Immunogenetics as an “Accredited Histocompatibility Testing Registered Facility.”」

    The Company reiterated the accreditation by the Japanese Society for Histocompatibility and Immunogenetics relating to the quality and contract testing structure for clinical testing.
  3. FY2021-Q2RestatedAnnual report

    「The Company’s registered laboratory has been accredited by the Japanese Society for Histocompatibility and Immunogenetics as an “Accredited Histocompatibility Testing Registered Facility.”」

    The Company reiterated the accreditation by the Japanese Society for Histocompatibility and Immunogenetics relating to the quality and contract testing structure for clinical testing.
  4. FY2021-Q1RestatedAnnual report

    「The Company’s registered laboratory has been accredited by the Japanese Society for Histocompatibility and Immunogenetics as an “Accredited Histocompatibility Testing Registered Facility.”」

    The Company reiterated the accreditation by the Japanese Society for Histocompatibility and Immunogenetics relating to the quality and contract testing structure for clinical testing.
  5. FY2020RestatedAnnual report

    「The Company’s registered health inspection laboratory has been accredited by the Japanese Society for Histocompatibility and Immunogenetics as an Accredited Histocompatibility Testing Registered Facility, satisfying an important requirement for medical institutions considering outsourcing the relevant clinical testing.」

    The Company reiterated its accreditation by the Japanese Society for Histocompatibility and Immunogenetics as a track record supporting quality and testing accuracy.
  6. FY2020-Q3AdvancedAnnual report

    「The Company’s registered health inspection laboratory has been accredited by the Japanese Society for Histocompatibility and Immunogenetics as an Accredited Histocompatibility Testing Registered Facility, satisfying an important requirement for medical institutions considering outsourcing the relevant clinical testing.」

    The Company disclosed its accreditation by the Japanese Society for Histocompatibility and Immunogenetics as an Accredited Histocompatibility Testing Registered Facility for clinical testing related to organ transplantation, demonstrating a specific accreditation record supporting its quality and contract testing structure.
  7. FY2017First statedAnnual report

    「In addition to the quality control standards required of registered health inspection laboratories, the Company actively encourages testing personnel to participate in QC workshops and other events organized by academic societies, and focuses on improving technical capabilities and testing accuracy.」

    The Company disclosed its ongoing policy of complying with statutory standards for its clinical testing business, participating in QC workshops, and improving technical capabilities and testing accuracy.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for ReproCELL yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Ensuring Clinical Laboratory Test Accuracy and Quality Control Activities | ReproCELL Incorporated (4978) | Komori